Treant Ziekenhuiszorg Stichting
- Address
- Dr. G.H. Amshoffweg 1, 7909 AA Hoogeveen, The Netherlands
Cardiovascular Diseases
Research at Treant Ziekenhuiszorg Stichting includes a strong focus on cardiovascular diseases, especially conditions such as hypertension, atherosclerotic cardiovascular disease, and prevention of heart failure. These trials are designed to test new treatment strategies, reduce major heart-related events, and improve long-term outcomes for people at elevated cardiovascular risk.
- High-risk cardiovascular disease without prior heart attack or stroke
- Resistant and uncontrolled hypertension
- Prevention of heart failure and cardiovascular death
- Testing therapies that lower blood pressure and reduce cardiac risk
The site is also involved in studies combining cardiovascular care with kidney protection, reflecting a broader effort to improve outcomes across linked chronic diseases.
Metabolic and Weight-Related Disorders
Another major area of research is nutritional and metabolic diseases, with trials centered on obesity, overweight, and type 2 diabetes. These studies aim to evaluate new therapies that support weight loss, improve blood sugar control, and lower the risk of complications tied to metabolic disease.
- Obesity and overweight with diabetes or cardiovascular risk
- Type 2 diabetes and glycemic control
- Improving metabolic health and reducing treatment-related complications
- Assessing whether new medicines can support weight and glucose management
This research also extends to related conditions such as severe hypertriglyceridemia and broader metabolism-linked health problems, showing a wide interest in chronic metabolic care.
Diabetes and Pregnancy
The site contributes to studies on diabetes across different stages of life, including type 1 diabetes, type 2 diabetes, and gestational diabetes mellitus. These trials are focused on preserving insulin function, improving glucose control, and understanding how treatment during pregnancy may affect both mother and child.
- Recently diagnosed type 1 diabetes in adolescents and adults
- Gestational diabetes and maternal-fetal outcomes
- Type 2 diabetes management and related risks
- Long-term follow-up of treatment effects after pregnancy
By exploring both short- and long-term outcomes, Locatie Scheper supports research aimed at better diabetes care from diagnosis through later life.
Oncology
Clinical trials in neoplasms at this site include studies in advanced solid tumors, multiple myeloma, non-Hodgkin lymphoma, T-cell prolymphocytic leukemia, and esophagogastric cancer. The main goal is to evaluate new cancer treatments, understand their safety, and identify which patients may benefit most from targeted therapies.
- Advanced solid tumors and blood cancers
- Targeted treatments matched to tumor biology
- Evaluating anti-cancer activity and tolerability
- Improving access to promising oncology therapies
This area reflects a precision-medicine approach, with research designed to better match treatment to the biological features of each cancer.
Kidney and Cardiometabolic Protection
A further research theme combines cardiovascular, metabolic, and kidney disease care. These trials are examining whether newer therapies can protect kidney function, reduce heart-related events, and improve outcomes in people living with chronic kidney disease, type 2 diabetes, and related cardiometabolic conditions.
- Chronic kidney disease with diabetes or hypertension
- Reducing worsening kidney function
- Lowering risk of heart failure and cardiovascular death
- Testing combined approaches for heart and kidney protection
This work highlights the close connection between heart, kidney, and metabolic health, and the site’s role in studying therapies that may benefit several organ systems at once.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Treant Ziekenhuiszorg Stichting
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascular Events in Participants at High Cardiovascular Risk | Merck Sharp & Dohme LLC | Phase III | Not Recruiting | Jun 2024 | — |
IMP list
lock Showing 1 of 5 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Isis 678354 Sodium Salt | 2 | Unknown | 2023-05-17 | 2023-06-08 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.